← All trials
NCT02300558
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 17, 2014
- Primary completion
- Feb 15, 2017
- Completion date
- Feb 15, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 41
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Gilead SciencesLead sponsor
- Gilead SciencesStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.